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Background. Invasive aspergillosis (IA) is associated with high mortality. Successful outcome with treatment
is linked to early diagnosis. The utility of classic diagnostic methods, however, is limited.
Methods. To aid in the diagnosis of IA, we retrospectively assessed our diagnostic service, using real-time
polymerase chain reaction (PCR) and galactomannan sandwich enzyme-linked immunosorbent assay (ELISA).
Results. A total of 203 patients at risk of invasive fungal infection were screened by PCR, and 116 of the
patients were also tested by ELISA. The patient group comprised 176 patients with hematological malignancy and
28 control patients with evidence of invasive candidal infection. Consensus European Organisation for Research
and Treatment of Cancer and Mycoses Study Group criteria were used to classify fungal infection, which, by
definition, excluded the PCR result. The PCR method was sensitive (up to 92.3% sensitivity) and specific (up to
94.6% specificity) and had good agreement with the galactomannan ELISA (76.7%) and high-resolution computed
tomography scan results.
Conclusions. A negative PCR result can be used to rule out IA and to limit the need for empirical antifungal
therapy; thus, it has a role in diagnosing IA infections, especially in combination with antigen testing. PCR-positive
cases classified as “false positives” regularly reflect the limitations of classic microbiological procedures or restricted
use of consensus clinical methods employed to classify infection.
The incidence of invasive aspergillosis (IA) is increasing
[1]. Difficulties with diagnosis mean that most invasive
fungal infections are proven only at autopsy. Histo-
pathological analysis can establish diagnosis of a fila-
mentous fungal infection but rarely can identify the
agent at a species level. High-resolution CT scan of the
chest may be a useful adjunctive investigation in di-
agnosis but cannot confirm infection, and results may
be transient [2, 3].
DNA-based methods have shown potential in the
definitive diagnosis of invasive fungal infections. De-
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pending on the target gene, assays demonstrate high
specificity, with figures of 100% [4–6], 93% [7], and
92% [8] reported. Other factors, including the efficacy
of the DNA extraction [9, 10], quality of primers (dimer
formation and/or nonspecific amplification), type of
PCR reaction (block-based PCR [11], nested PCR [12],
or real-time PCR [5]), size of population studied, type
of disease [13], and sample type (plasma, whole blood,
or bronchoalveolar lavage [BAL] [14–16]) will affect
the sensitivity of the assay.
The method of Williamson et al. [12] has been used
in our laboratories for investigational diagnosis. Oc-
casional problems with nonspecific amplification hin-
dering the interpretation of results, plus the additional
processing time required to perform gel electrophoresis,
suggested that the assay could be improved by using
an Aspergillus-specific probe and the Roche Light Cycler
for the second round of nested PCR. The aim of this
study was to evaluate the performance of the modified
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assay in a clinical setting as an adjunct to diagnosis by accepted
European Organisation for Research and Treatment of Cancer
and Mycoses Study Group (EORTC-MSG) criteria [17].
PATIENTS AND METHODS
Patient Group
A group of 203 patients at risk of invasive fungal infection were
tested by real-time PCR over a 13-month period (November
2003–December 2004). The majority (176) were hematology
patients, with 133 receiving remission-induction therapy for
acute leukemia (68 patients) or undergoing stem cell trans-
plantation (65 patients) (table 1). The mean age of patients
was 48 years (table 1). The EORTC-MSG criteria [17] (outlined
in table 2) were used to classify fungal infection (table 1).
Stem cell transplant recipients and patients with acute mye-
loblastic leukemia received itraconazole prophylaxis, and pa-
tients with acute lymphoblastic leukemia received fluconazole
prophylaxis. Piperacillin/tazobactam and amikacin were used
for empirical treatment of febrile neutropenia, with lipid for-
mulations of amphotericin or echinocandin added for refrac-
tory fever after 96 h.
In accordance with proposed standards of care [3], high-
resolution CT scans were requested by clinicians but were delayed
or refused on some occasions (resulting compliance, 36.9%), and
bronchoscopic analysis was performed if an undiagnosed respi-
ratory pathogen was suspected. Nine patients had Aspergillus
species cultured from respiratory specimens (7 sputum and 2
BAL specimens). Aspergillus fumigatus was the most common
species isolated ( ), although Aspergillus niger and Aspergillusnp 7
terreus were also cultured. Contemporaneous samples for PCR
and galactomannan ELISA (BioRad) were taken at the decision
of the clinicians, who were advised to obtain samples twice weekly
(Monday and Thursday) as part of the investigation of febrile
neutropenia in high-risk patients, although sampling was not
always consistent (compliance, 50%).
The galactomannan ELISA was performed as described by
the manufacturer. To comply with European Directive 98/79/
EC, only index values of 1.5 were reported as positive, al-
though the absolute values were recorded, and the number of
probable cases of IA were not affected by a reduction of the
index factor to 0.5.
Retrospectively, patients were assessed for evidence of bac-
terial or viral infections according to standard diagnostic pro-
tocols. Significant pathogens isolated from blood cultures (ex-
cluding single isolates of coagulase-negative Staphylococcus),
positive cytomegalovirus PCR results, or positive immunofluo-
rescence findings for respiratory viruses resulted in the reclas-
sification of possible IA cases as “at-risk” cases. Probable cases
were not reclassified, as the evidence for probable IA retains
its weight even if other infections are diagnosed. However, no
patients with probable IA had evidence of any alternative sig-
nificant infection. Hematology patients without host factors or
with an alternative cause of fever with no clinical or micro-
biological features of invasive fungal infection were classified
as at-risk. In addition, 28 nonhematology, critical-care patients
with clinical and microbiological evidence of invasive candidal
infections and no evidence of IA were included as a control
population to test the specificity of the assay and were classified
as at-risk (table 1).
Sample Type
For PCR, twice-weekly 2-mL whole blood samples collected in
EDTA vacutainers were requested and were stored at 80C
until testing. Clinicians requesting Aspergillus antigen tests were
instructed to collect clotted blood specimens twice weekly, and
2 mL of serum was removed and was stored at 80C until
testing. Samples were stored for up to 7 days before testing.
DNA Extraction
From fungal cultures. Cultures were grown overnight at 37C
in glucose broth. The following day, fungal biomass (1–2 mL
of culture) was harvested by centrifugation (at 5300 g for 10
min), and the supernatant was discarded. Fungal DNA was
then extracted as described, with the exclusion of the blood
lysis steps.
From clinical specimens. Fungal DNA was extracted from
blood using a modified version of the semiautomated method
described by Loeffler et al. [9]. All manual steps of the extrac-
tion procedure were performed in a class 2 laminar flow cabinet.
After lysis of the RBCs and WBCs [18], samples were bead-
beaten with ∼20 mL of acid-washed glass beads (1180 microns;
Sigma) and were pulse-centrifuged before being washed with
200 mL of molecular-grade water. The 200-mL washings were
transferred into a MagNA Pure LC sample cartridge and were
loaded onto a MagNA Pure platform (Roche), and the extrac-
tion was completed using the Total NA serum, plasma, blood
kit, and program (Roche). The DNA was eluted in a volume
of 100 mL.
In each clinical run, A. fumigatus conidia were quantified
using a Fuchs Rosenthal counting chamber, and known levels
of A. fumigatus (10–20 colony-forming units [cfu]/mL) were
spiked into (i.e., added to) whole blood samples collected in
EDTA vacutainers from a healthy donor, to provide a positive
extraction control. Nonspiked blood from a healthy donor was
used as a negative extraction control.
PCR
Production of standards. By use of primers (AF4 and AR1)
and methods described elsewhere [12], a 270-bp PCR prod-
uct was amplified from A. fumigatus DNA (clinical isolate).
PCR products were cloned using the TOPO TA Cloning kit
(Invitrogen), incorporating a pCRII-TOPO vector and One
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Table 1. Data for the patients ( ) tested by PCR.np 203
Characteristic Value
Age group, years
!10 6
11–20 15
21–30 9
31–40 28
41–50 23
51–60 45
61 75
Not given 2
Diagnosis/condition
Acute myeloid leukemia 58
Acute lymphoblastic leukemia 10
Chronic myeloid leukemia 2
Chronic lymphoblastic leukemia 3
Other leukemia 2
Lymphoma 22
Myeloma 13
Allogeneic SCT and nonspecified malignancy 65
Nonhematological disordera 28
Galactomannan ELISA performed (%) 116 (57)
No. of samples tested (range per patient [ ])np 203 401 (1–14)
No. of samples with IA classification
Proven/probable IA (range per patient [ ])np 14 70 (2–14)
Possible IA (range per patient [ ])np 40 117 (2–7)
At-risk (range per patient [ ])np 149 214 (1–10)
NOTE. Data are no. of patients, unless otherwise indicated.
a Nonhematological cases included respiratory failure, esophageal rupture,
cystic fibrosis, diabetes, pneumonia, premature birth, renal failure, cirrhosis,
or postsurgical complications following cardiac or abdominal surgery. All cases
had clinical and microbiological evidence of invasive candidal infections (11
proven candidemia cases and 7 probable and 10 possible cases of invasive
candida infection). Proven cases were defined by the isolation of Candida from
sterile sites (excluding drain fluids and urine) and by histopathological analysis.
Probable invasive Candida infections were classified by the presence of risk
factors (surgery, antibiotic use, prematurity, venous catheters, parenteral nu-
trition, and immunosuppression), with clinical signs of infection (fever unre-
sponsive to antibacterial antibiotics) and Candida colonization at multiple (12)
noncontiguous anatomical sites. Furthermore, in neonates, persistent candi-
duria was considered significant. Possible invasive Candida infections were
defined by clinical signs of infection linked to predisposing conditions, such
as necrotizing pancreatitis, anastamotic breakdown or recurrent perforation of
the bowel, or spontaneous esophageal rupture with no evidence of a clinically
significant bacteremia [14]. SCT, stem cell transplant.
Shot Top 10F chemically competent Escherichia coli. Plasmids
were extracted (S.N.A.P. MiniPrep Kit; Invitrogen) from Luria-
Bertani and ampicillin broth cultures and were quantified using
a GeneQuant DNA/RNA calculator (Amersham Biosciences).
To confirm the identity of the insert, the plasmids were screened
with direct PCR, with use of the primers AF4 and AR1, and
were digested with the restriction enzyme EcoRI.
Oligonucleotide design. Aspergillus-specific primers de-
scribed elsewhere [12] were used. The probe was designed to
bind an Aspergillus-specific region of the 28S rRNA gene am-
plified by the primers ASF1 and ADR1. Analogous sequences
from 45 strains from 13 species of Aspergillus were compared
for homology. Sequences from representative Aspergillus species
were compared with the sequences from 23 species from 10
different genera. A hydrolysis (TaqMan) probe was designed to
hybridize to a sequence that was specific to the genus Asper-
gillus. The binding sites for the hydrolysis probe ASP28P (FAM-
CATTCGTGCCGGTGTACTTCCCCG-TAMRA) and primers
ASF1 and ADR1 on A. fumigatus (NCBI Nucleotide Database
accession number AJ438345) are at positions 453–486, 392–
412, and 560–575, respectively.
Roche Light Cycler assay. Real-time PCR was performed
using the Aspergillus-specific primers and probes (ASF1, ADR1,
and ASP28P). For amplicon detection, the Light Cycler Fast
Start DNA Master Hybridisation Probes kit was used. The PCR
mix contained 1 Fast Start reaction mix, 0.75 mmol/L of each
primer, 0.4 mmol/L of probe, 4 mmol/L of MgCl2, and DNA
template, for a final volume of 20 mL. PCR conditions were 1
cycle at 95C for 15 min followed by 60 cycles at 95C for 5 s
and 60C for 30 s, while data were acquired at channel F1/F2.
In addition to extraction controls for clinical runs, PCR stan-
dards in the form of cloned PCR products (200, 20, and 5 input
copies) and duplicate DNA-free PCR controls (molecular-grade
water) were included in every run. PCRs with positive results
were repeated for confirmation and were considered clinically
significant when serial positive results were generated during a
single episode, although widespread use of empirical antifungal
agents was a possible confounding factor affecting positivity.
To further enhance the sensitivity of the assay, it was nec-
essary to perform a nested PCR. The first round of the nested
PCR was done as described elsewhere [12], but primer con-
centrations were increased to 0.4 mmol/L, and DNA template
was increased to 10 mL. On completion of the first round, 10
mL of the amplicon was used as the template for the second
round on the Light Cycler, by use of conditions described above.
Controls were as described above except for 2 additional DNA-
free PCR controls.
RESULTS
Aspergillus PCR detection limits, reproducibility, and cross-
reactivity. The detection limit for the assay was determined
for both cfu and plasmid copy number. Serial dilutions showed
that the lower limit of detection of the Light Cycler assay alone
was ∼2 input copies, although, for 100% reproducibility, 5
input copies were necessary (figure 1). The standard curve for
the Aspergillus assay is shown in figure 2.
The single-round Light Cycler assay could reproducibly detect
10 cfu/mL spiked in blood, with a lower detection limit of !10
cfu (figure 1). The nested Aspergillus assay improved detection
limits to 1 input copy and !5 cfu reproducibly detected.
Four species of Aspergillus (A. fumigatus, Aspergillus fla-
vus, Aspergillus nidulans, and A. niger), a strain of Fusarium
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Table 2. Criteria used to determine certainty of invasive aspergillosis (IA)
infection.
IA infection criteria
Host factors
Antibacterial refractory fever (for 196 h)
Neutropenia (neutrophil count, !500 neutrophils/mm3 for 110 days)
Fever of unknown origin
Prolonged steroid use (13 weeks)
Graft-versus-host disease
Microbiological factors
Positive result of culture of sputum, bronchoalveolar lavage, or sinus specimen
Positive microscopic analysis result
Positive galactomannan antigen test result
Clinical factors
Major
CT findings (halo, air crescent)
Nodular skin rash
Minor
New pleural infiltrate (on chest radiograph)
Pleuritic chest pain
Shortness of breath
Cough
Hemoptysis
Pleural rub
NOTE. Proven IA is defined by histological evidence with a concomitant positive culture
result. Probable IA is defined by a host factor plus a microbiological factor plus 1 major (or 2
minor) clinical factors. Possible IA is defined by a host factor plus a microbiological factor or
1 major (or 2 minor) clinical factors. Criteria from [17].
solani, and 15 species of yeast (4 genera) were tested for cross-
reactivity. All Aspergillus species tested were detected by the
assay, whereas the 12 Candida species (Candida albicans, Can-
dida dubliniensis, Candida famata, Candida glabrata, Candida
guilliermondii, Candida kefyr, Candida krusei, Candida lipoly-
tica, Candida lusitaniae, Candida parapsilosis, Candida rugosa,
and Candida tropicalis), Cryptococcus neoformans, Rhodotorula
rubra, Saccharomyces cerevisiae, and F. solani were not detected
by the assay.
Aspergillus PCR sensitivity and specificity with clinical
specimens. There were 14 cases (11 with acute leukemia and/
or receipt of allogeneic stem cell transplantation [AL/SCT]) of
proven/probable IA, 40 cases [13 AL/SCT] of possible IA, and
149 cases (109 AL/SCT) classified as at-risk for IA, generating
an incidence rate of 6.9% (9.2% in the AL/SCT population).
A total of 401 whole blood samples collected in EDTA vacu-
tainers from 203 patients (range per patient, 1–14 samples)
(table 1) were tested by PCR, with 51 patients having at least
1 specimen test positive by Aspergillus PCR, but, more signif-
icantly, 26 patients (12.8%) had serial positive results (range,
2–10 positive results). Only patients with serial positive results
were considered to be PCR positive. Single positive PCR results
among multiple samples were considered false-positive results,
and single positive PCR results for a specimen with no other
samples were excluded from statistical analysis, although con-
sidering them false-positive results had little impact on the assay
performance. One patient classified as having probable IA was
excluded from analysis because samples were sent 2 weeks after
the diagnosis of probable disease. During the intervening pe-
riod, the patient had received appropriate antifungal therapy.
PCR positivity rates were higher in the proven and probable
IA categories and correlated well with radiological markers—
10 of the 12 patients with PCR-positive, proven/probable IA
had CT scans of the chest suggestive of possible fungal infection.
Furthermore, 32 of the 33 patients whose CT scan findings
were negative also had negative PCR results. In total, 75 patients
underwent a CT scan: 18 scans were suggestive of an invasive
fungal infection, 24 were nonspecific, and 33 were negative.
The positivity rate for patients with proven/probable IA with
serial positive PCR results was 92.3%, compared with 15.0%
for those with possible IA (difference, 77.3%; 95% CI, 48.1%–
87.5%) and 5.4% for at-risk groups (difference, 86.9%; 95%
CI, 60.9%–93.8%) (table 3). The sample positivity rate by use
of serial positives for proven/probable cases was 60.0%, where-
as, for possible and at-risk cases, it was 14.5% (difference,
45.5%; 95% CI, 31.6%–57.4%) and 10.7% (difference, 49.3%;
95% CI, 36.6%–64.0%), respectively (table 3).
The statistical performance of the assay was calculated using
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Figure 1. The detection limits of the single-round Aspergillus PCR using colony-forming units (cfu) (A) or plasmid copy number (B)
different definitions of disease status [7]. The sensitivity, spec-
ificity, positive predictive value, and negative predictive value
of the Aspergillus PCR are shown in table 4.
DISCUSSION
The value of PCR for diagnosing invasive fungal infections has
yet to be determined, and PCR results are not included in the
current EORTC-MSG criteria for defining invasive fungal in-
fection. Although PCR methods may lack standardization and
optimization across centers, antigen detection provides varied
performance in terms of sensitivity (29%–100% [19]). It is
included in the consensus criteria because of its commercial
availability and good specificity (185% [19]), despite a lack of
agreement regarding the correct cutoff for positivity.
By use of serial positive PCR results, only a slight increase
in sensitivity (92.3%) and a slight decrease in specificity (94.6%)
were observed when compared with the original method [12].
However, a depreciation of 40% was seen for the positive pre-
dictive value by use of the Light Cycler–based assay. This de-
crease can be explained by the 8 patients with serial positive
PCR results who lacked EORTC-MSG clinical or microbiolog-
ical criteria for IA and were classified as at-risk. Of a median
of 5 samples tested per patient (range, 3–8 samples tested per
patient), the median number of positive samples per patient
was 3. In 4 patients, the positive PCR results spanned up to 4
consecutive weeks, during which the patients remained febrile
and neutropenic, with no other cause for their fever. Three of
these patients received antifungal therapy, with 2 patients be-
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Figure 2. Standard curve for the Aspergillus PCR, whereYp1.5705ln(X)
+42.71. Both the correlation coefficient (r ) and the correlation coefficient
squared (R 2) were 1.00. The mean (SD) crossing-point for 5 input copies
was 38.66 ( 0.78) cycles. The maximum variation in crossing-point for
5 input copies was 1.44 cycles (3.7%).
Table 3. Correlation between detection of Aspergillus by PCR and the level of confidence in invasive
aspergillosis (IA) infection.
Classification
No. of patients
with positive PCR
Patient
positivity rate, %
(95% CI)a
No. of
samples tested
(no. PCR
positive)
Sample
positivity rate, %
(95% CI)a
Single
positive
result
Serial
positive
results
Proven/probable IA ( )bnp 13 0 12 92.3 70 (42) 60.0
Possible IA ( )np 40 13 6 15.0 (48.1–87.5) 117 (30) 14.5 (31.6–57.4)
At-risk ( )np 149 12 8 5.4 (60.9–93.8) 214 (35) 10.7 (36.6–64.0)
a Positivity rates are only for patients with serial positive PCR results, and 95% CIs were generated for differences between
proven/probable, possible, and at-risk categories.
b One patient was excluded.
coming PCR negative; no follow-up specimens were available
from the third patient. All 3 patients who received antifungal
therapy survived. The fourth patient received no antifungal
therapy and died, although autopsy was not performed.
Jordanides et al. [20] documented the problem of serial pos-
itive PCR results in patients and commented on the difficulty
in determining an actual “false-positive” result from an early
“true-positive” result, reflecting the fact that PCR is more sen-
sitive than current diagnostic procedures. In clinical practice,
other adjunctive procedures required for consensus diagnostic
criteria usually are not performed or are performed at the
wrong time [3]. It seems inappropriate to use methods that are
rarely used antemortem (histopathology), have transient results
(CT), or are less sensitive (blood culture) as comparison in an
assessment of the performance of a PCR method, unless a
structured regimen of testing is in place for all methods. This
highlights the difficulties in determining a proven/probable case
of IA, and it is not unexpected that only 6% of patients with
IA receive a definite diagnosis [21], which emphasizes the need
for improved diagnostic methods [20, 22].
Analysis of specimen positivity rate showed that 60%, 14.5%,
and 10.7% of samples for proven/probable, possible, and at-
risk cases, respectively, were positive by PCR. The 95% CIs
confirm these differences and suggest that, 95% of the time,
the sample positivity rate for proven/probable cases would be
37%–64% greater than that for at-risk cases.
Since at-risk cases have low positivity rates for samples, serial
positive PCR results during 1 particular episode should be con-
sidered indicative of probable/possible IA. Applying these cri-
teria would mean that 7 of the 8 patients classified as at-risk
who had serial Aspergillus-positive PCR results could be re-
garded as having possible IA, and it would enhance specificity
and positive predictive values to 99.3% and 92.2%, respectively.
The high sensitivity of the assay has implications for initi-
ation and continuation of antifungal therapy. The excellent
negative predictive value (99.3%) will allow clinicians to with-
draw therapy in cases that have responded. No patients in this
study received a diagnosis of other filamentous fungal infec-
tions; however, the number of cases of non-Aspergillus fila-
mentous fungal infections is rising [23], and other assays [20]
are needed to avoid false-negative results of non-Aspergillus
infections or to withhold therapy.
The optimal specimen for the molecular detection of IA is
still not resolved. Some groups prefer whole blood samples
[8, 15], others prefer serum samples [24, 25], and some prefer
BAL samples [4, 26]. Serum has been reported to be an ap-
propriate sample for the diagnosis of IA [24]. However, only
free-circulating Aspergillus DNA will be targeted, because hy-
phae or phagocytosed intracellular fungal fragments will be
removed by clot formation and centrifugation.
If fungal fragments are present in blood, they should be
detectable by blood culture methods [24], particularly if lytic
systems are used [27, 28]. As few as 1–10 cfu of Aspergillus
conidia inoculated into blood culture bottles can be detected
within 24 h [29], but, in the clinical scenario, blood cultures
are rarely positive for Aspergillus (possibly because phagocytosis
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Table 4. Performance of Aspergillus PCR with use of different
definitions of disease status.
Value
Under invasive aspergillosis (IA) definitiona
A B C
Sensitivity 92.3 (66.7–98.6) 34.0 (22.7–47.4) 92.3 (66.7–98.6)
Specificity 94.6 (89.8–97.3) 94.6 (89.8–97.3) 92.6 (88.0–95.5)
PPV 60.0 (38.7–78.1) 69.2 (50.0–83.5) 46.2 (28.8–64.5)
NPV 99.3 (96.1–99.9) 80.1 (73.6–85.3) 99.4 (96.9–99.9)
NOTE. Data are percentage (95% CI). Statistics were calculated using
serial positive-PCR results. NPV, negative predictive value; PPV, positive pre-
dictive value.
a Under definition A, proven/probable cases are true positives, at-risk cases
are true negatives, and possible cases are excluded from statistical analysis;
under definition B, proven/probable/possible cases are true positives, and at-
risk cases are true negatives; under definition C, proven/probable cases are
true positives, and possible/at-risk cases are true negatives.
of fungal fragments by macrophages renders the fungal com-
ponent nonviable), whereas DNA can still be detected [30, 31].
Detection of A. fumigatus in a murine model with intravenously
induced fungemia 3 days after infection was 0% by blood cul-
ture and 100% by PCR [30].
Whole blood inoculated with DNA extracted from known
amounts of A. fumigatus (10–1000 cfu) was reextracted and
tested by both single-round and nested Aspergillus PCR meth-
ods, but no samples tested positive (results not shown). This
suggests that the procedure is not suitable for extracting free
DNA or that the DNA is degraded by DNAses present in the
blood. Results for this method correlate with proven/probable
cases of IA. Detecting DNA from nonviable or dead Aspergillus
hyphae circulating in the blood is a possible explanation.
BAL samples are reported to give higher sensitivities and
specificities than blood samples [32]. Although PCR sensitivity
may be improved by testing BAL samples, improved specificity
must be questioned. Indeed, 25% of BAL samples from healthy
donors are PCR positive through inhalation of airborne As-
pergillus spores [33]. Environmental contamination of blood
specimens is minimal, and blood is easier to obtain for initial
and repeated sampling [21].
In summary, we describe the evolution of a manual DNA-
extraction, nested-PCR method into a semiautomated real-time
PCR assay that has improved sensitivity without a major re-
duction in specificity. Like other groups [34], we believe that
if a patient has both PCR and galactomannan ELISA positive
results, then it is likely that the patient has fungal disease, and
we believe that both tests should be used to screen at-risk
patients, with the concurrent use of both assays allowing con-
firmation of diagnosis.
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